Friday, July 10, 2026

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo

São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Clinical program

OROS hydromorphone

Approved · small molecule · Cancer Pain

OROS hydromorphone for Cancer Pain is a Approved program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).

← All Janssen Cilag International NV projects Approved small molecule completed

Internal code CR100659

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Janssen Cilag International NV
Phase
Approved
Modality
small_molecule
Indication
Cancer Pain
Status
completed
Trials
1